About Atum
Atum is a company based in Newark (United States) founded in 2003. Atum offers products and services including Gene Design & Synthesis Services, Antibody Services, Cell Line Development, and Protein Expression Services. Atum operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
- Headquarter Newark, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dna 2.0, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$805.16 K (USD), Grant
Feb 07, 2011
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atum
Atum offers a comprehensive portfolio of products and services, including Gene Design & Synthesis Services, Antibody Services, Cell Line Development, and Protein Expression Services.
Offers design and synthesis of genes for research applications.
Provides antibody production and engineering solutions.
Develops stable cell lines for biologics manufacturing.
Handles expression and analytics of proteins.
People of Atum
Unlock access to complete
Funding Insights of Atum
Investors in Atum
Atum has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked |
Investor details for Atum
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atum
Investment portfolio details for Atum
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atum
Detailed financials for Atum
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atum Comparisons
Peer comparison for Atum
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atum
Atum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
Detailed competitors of Atum
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atum
Complete news archive for Atum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atum
Atum was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Atum is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Atum is a synthetic biology company specializing in molecular biology and protein engineering. The company has a range of specialized products including the Electra Vector system (a single-tube 5-minute cloning platform), bacterial, mammalian and yeast protein expression vectors and expression strains of Pichia pastoris, ProteinPaintbox range of synthetic fluorescent proteins (non-Aequorea fluorescent proteins) and chromogenic proteins, CRISPRCas9 services that include the companys All-in-One NickaseNinja vector constructs for expression of dual gRNAs. The companys custom synthetic biology services include genome engineering, gene synthesis, protein engineering, and their proprietary codon optimization system for gene synthesis, called GeneGPS. Atum has also developed a protein engineering platform based on machine learning and Design of Experiment (DoE) called ProteinGPS. The started off as DNA2.0, but changed its name to Atum in December 2016. They offer their services for cell line development, protein expression (lab and large scale), gene synthesis and protein engineering.
Atum's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.
Atum offers Gene Design & Synthesis Services, Antibody Services, Cell Line Development, and Protein Expression Services.
Atum has 1 investor. Key investors include National Science Foundation.